Abbott Laboratories ABT
Regular-session close
After hours · Nov 20, 7:46 PM ET
- YTD
- -17.79%
- 1 year
- -16.92%
5D -6.62 (-6.03%)
- Market cap
- 178.39B
- Revenue (ttm)
- 48.23B
- Profit margin
- 9.75%
- EPS (ttm)
- 2.68
- Shares out
- 1.73B
- P/E ratio
- 38.43
- Forward P/E
- 17.33
- Dividend
- 2.52 (2.43%)
- Ex-dividend date
- Oct 15, 2026
- YTD return
- -17.79%
- 1-year return
- -16.92%
- Volume
- 7.30M
- Avg volume
- 8.93M
- Open
- 104.32
- Previous close
- 103.87
- Day's range
- 102.80 – 105.50
- 52-week range
- 82.56 – 128.90
- Beta
- 0.54
- Analysts
- Strong Buy
- Price target
- 119.60 (+16.1%)
- Earnings date
- Jan 28, 2027
- 50-day average
- 103.87
Key statistics
- 200-day average
- 101.48
- Enterprise value
- 207.63B
- PEG ratio
- 1.50
- Price / sales
- 3.69
- Price / book
- 3.49
- Payout ratio
- 92.54%
- Revenue growth
- 14.50%
- Free cash flow
- 6.07B
- Total cash
- 4.30B
- Total debt
- 31.44B
- Return on equity
- 9.14%
- Short % of float
- 1.23%
Fundamental scorecard
16 of 25 checks passed on ABT’s reported financials
16of 25 checks passed
- Value 2 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 3 of 5
- Dividend 4 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 100.00
- Target (mean)
- 119.60
- Target (high)
- 130.00
- Strong buy5
- Buy19
- Hold4
- Sell0
- Strong sell0
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 1.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 1.64 | — | — | — |
| Oct 21, 2026 | Sep 30, 2026 | 1.42 | 1.42 | 0.00 | 0.00% |
| Jul 16, 2026 | Jun 30, 2026 | 1.28 | 1.31 | +0.03 | +2.34% |
| Apr 16, 2026 | Mar 31, 2026 | 1.14 | 1.15 | +0.01 | +0.88% |
| Jan 22, 2026 | Dec 31, 2025 | 1.50 | 1.50 | 0.00 | 0.00% |
| Oct 15, 2025 | Sep 30, 2025 | 1.30 | 1.30 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2026 | Leerink Partners | up | Market Perform | Outperform |
| Oct 27, 2026 | Argus Research | down | Buy | Hold |
| Oct 23, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 22, 2026 | Citigroup | main | Buy | Buy |
| Oct 22, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 22, 2026 | Wells Fargo | main | Overweight | Overweight |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- abbott.com
News
Abbott Has Raised Its Dividend for 54 Years. These 3 Healthcare Stocks Keep Paying More
Abbott (ABT) Up 1.3% Since Last Earnings Report: Can It Continue?
3 Dividend Kings to Buy in November and Never Sell Abbott Initiates VOYAGER CE Clinical Trial Evaluating Investigational Encantor Transcatheter Aortic Valve Implantation Software-Guided Balloon-Expandable System For Treating Symptomatic Severe Aortic Stenosis
Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis
This Abbott Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
This Abbott Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Leerink Partners Upgrades Abbott Laboratories to Outperform, Announces $124 Price Target
Ken Griffin Dumps SpaceX, Amazon; Buys ARKK and Bets Big on Marvell
The Winners Inside SCHD - November 2026
Your note
Sign in to keep a note on ABT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN HUBERT L. | Officer | Stock Award(Grant) | Feb 24, 2025 | 200,281 |
| BOUDREAU PHILIP P | Chief Financial Officer | Purchase | Apr 22, 2026 | 0 |
| CONROY KEVIN T | Director | Stock Award(Grant) | Apr 23, 2026 | 133,737 |
| EARNHARDT LISA D | Officer | Stock Award(Grant) | Feb 23, 2026 | 98,984 |
| FORD ROBERT B. | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 24, 2026 | 522,664 |
| MORELAND MARY K | Officer | Sale | Mar 1, 2026 | 116,136 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.76% | 151,666,065 | 15.60B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 113,251,899 | 11.65B | Sep 29, 2026 |
| State Street Corporation | 4.70% | 81,431,110 | 8.38B | Sep 29, 2026 |
| Charles Schwab Investment Management, Inc. | 3.30% | 57,160,750 | 5.88B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 2.77% | 47,941,543 | 4.93B | Sep 29, 2026 |
| Capital Research Global Investors | 2.60% | 44,980,846 | 4.63B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 55,297,279 | 5.69B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 2.75% | 47,631,745 | 4.90B | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.61% | 45,138,490 | 4.64B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 23,056,907 | 2.37B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 22,487,991 | 2.31B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 21,408,918 | 2.20B | Sep 29, 2026 |
